Intra- and postprocedural thrombosis are major complication of aneurysmal coil embolization, stent-assisted coiling, and pipeline embolization. The common but unproven practice of dual antiplatelet therapy with aspirin and a P2Y12 inhibitor in neuro-endovascular patients is inferred from the cardiology literature without large clinical trials to support it in neuro-endovascular patients.
Objective:
We conducted an electronic survey to identify practice variations surrounding the use of oral antiplatelets in patients undergoing endovascular neuro-interventional procedures across neuro-endovascular centers in the United States.
Methods:
An electronic survey was distributed via the Web. Any practicing neuro-intensive care unit (ICU), neuro-interventional or stroke physician, pharmacist, physician assistant, or nurse practitioner was eligible to respond to this survey between June and October 2017.
Results:
A total of 33 responses were collected during the survey period. A response rate of 16% was calculated after taking into account all comprehensive stroke centers in the United States. Aspirin and clopidogrel was the standard-of-care antiplatelet regimen utilized in the majority of institutions (82%). Alternatively, 4 institutions used monotherapy (aspirin [n = 2], clopidogrel [n = 1], either aspirin or clopidogrel [n = 1]) and 2 institutions reported practitioner-dependent practices. Just under half of the centers reported ticagrelor as the primary alternative in clopidogrel nonresponders (48%).
Conclusion:
Dual antiplatelet therapy with aspirin and clopidogrel appears to be standard of care in this setting based on our survey. About half of responding institutions use ticagrelor in cases where clopidogrel resistance is suspected. Large society-wide patient registries are needed to provide data for future safety and efficacy studies.
ZhouGZhuYQSuM, et al.Flow-diverting devices versus coil embolization for intracranial aneurysms: a systematic literature review and meta-analysis. World Neurosurg. 2016;88:640–645.
2.
PandeyASKoebbeCRosenwasserRH, et al.Endovascular coil embolization of ruptured and unruptured posterior circulation aneurysms: review of a 10-year experience. Neurosurgery. 2007;60(4):626–637.
3.
SongJKNiimiYFernandezPM, et al.Thrombus formation during intracranial aneurysm coil placement: treatment with intra-arterial abciximab. Am J Neuroradiol. 2004;25(7):1147–1153.
4.
TanLAKeigherKMMunichSA, et al.Thromboembolic complications with pipeline embolization device placement: impact of procedure time, number of stents and pre-procedure P2Y12 reaction unit (PRU) value. J Neurointerv Surg. 2015;7(3):217–221.
5.
ShahRRashidAHwangI, et al.Meta-analysis of the relative efficacy and safety of oral P2Y12 inhibitors in patients with acute coronary syndrome. Am J Cardiol. 2017;119(11):1723–1728.
6.
Sheikh RezaeiSGeroldingerAHeinzeG, et al.P3699Clopidogrel, prasugrel, or ticagrelor use and clinical outcome in patients with acute coronary syndrome: a nationwide long-term registry analysis from 2009 to 2014. Eur Heart J. 2017;38(suppl_1).
7.
Plavix (clopidogrel) package insert. Sanofi-Synthelabo. New York, NY; 2002.
8.
KangHHanMHKwonBJ, et al.Is clopidogrel premedication useful to reduce thromboembolic events during coil embolization for unruptured intracranial aneurysms?Neurosurgery. 2010;67(5):1371–1376.
9.
YamadaNKCrossDT IIIPilgramTK, et al.Effect of antiplatelet therapy on thromboembolic complications of elective coil embolization of cerebral aneurysms. Am J Neuroradiol. 2007;28(9):1778–1782.
10.
SofiFMarcucciRGoriAM, et al.Clopidogrel non-responsiveness and risk of cardiovascular morbidity. Thromb Haemost. 2010;103(4):841–848.
11.
SerebruanyVLSteinhublSRBergerPB, et al.Variability in platelet responsiveness to clopidogrel among 544 individuals. J Am Coll Cardiol. 2005;45(2):246–251.
12.
WilkinsonGR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005;352(21):2211–2221.
13.
DestaZZhaoXShinJG, et al.Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41(12):913–958.
LauWCGurbelPAWatkinsPB, et al.Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation. 2004;109(2):166–171.
16.
Effient [package insert]. Indianapolis, IN: Daiichi Sankyo, Inc. and Eli Lilly and Company. 2013.
17.
NiitsuYJakubowskiJASugidachiA, et al.Pharmacology of CS-747 (prasugrel, LY640315), a novel, potent antiplatelet agent with in vivo P2Y12 receptor antagonist activity. In: Seminars in Thrombosis and Hemostasis. New York, NY: Thieme Medical. 2005;31(2):184–194.
18.
ShameemRHamidMSRandhawaA, et al.P2Y12 Antagonists: pharmacology, efficacy and patient considerations. J Cardiovascu Dis. 2014;2(2):91–100.
19.
CapodannoDDharmashankarKAngiolilloDJ. Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist. Expert Rev Cardiovasc Ther. 2010;8(2):151–158.
20.
Brilinta [package insert]. Wilmington, DE: AstraZeneca; 2011.
FaughtRWSattiSRHurstRW, et al.Heterogeneous practice patterns regarding antiplatelet medications for neuroendovascular stenting in the USA: a multicenter survey. J Neurointerv Surg. 2014;6(10):774–779.
23.
GuptaRMooreJMGriessenauerCJ, et al.Assessment of dual-antiplatelet regimen for pipeline embolization device placement: a survey of major academic neurovascular centers in the United States. World neurosurg. 2016;96:285–292.
24.
LinSCuiHBChenXM, et al.Clinical application of VerifyNow-P2Y12 assay in evaluation of platelet inhibition efficacy of clopidogrel. Zhonghua xin xue guan bing za zhi. 2012;40(8):662–666.
25.
NordeenJDPatelAVDarracottRM, et al.Clopidogrel resistance by P2Y12 platelet function testing in patients undergoing neuroendovascular procedures: incidence of ischemic and hemorrhagic complications. J Vasc Interv Radiol. 2013;6(1):26.
26.
AkbariSHReynoldsMRKadkhodayanY, et al.Hemorrhagic complications after prasugrel (Effient) therapy for vascular neurointerventional procedures. J Neurointerv Surg. 2013;5(4):337–343.
27.
PrabhakaranSWellsKRLeeVH, et al.Prevalence and risk factors for aspirin and clopidogrel resistance in cerebrovascular stenting. Am J Neuroradiol. 2008;29(2):281–285.
28.
GasparyanAY. Aspirin and clopidogrel resistance: methodological challenges and opportunities. Vasc Health Risk Manag. 2010;6:109.
29.
KimKSFraserJFGrupkeS, et al.Management of antiplatelet therapy in patients undergoing neuroendovascular procedures. J Neurosurg. 2017;129:1–16.
30.
WiviottSDBraunwaldEMcCabeCH, et al.Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001–2015.
31.
StetlerWRChaudharyNThompsonBG, et al.Prasugrel is effective and safe for neurointerventional procedures. N Engl J Med. 2013;5(4):332–336.
32.
JonesGMTwillaJDHoitDA, et al.Prevention of stent thrombosis with reduced dose of prasugrel in two patients undergoing treatment of cerebral aneurysms with pipeline embolisation devices. J Neurointerv Surg. 2013;5:e38.
33.
HaEChoWSKimJE, et al.Prophylactic antiplatelet medication in endovascular treatment of intracranial aneurysms: low-dose prasugrel versus clopidogrel. Am J Neuroradiol. 2016;37(11):2060–2065.
34.
SedatJChauYGaudartJ, et al.Prasugrel versus clopidogrel in stent-assisted coil embolization of unruptured intracranial aneurysms. Interv Neuroradiol. 2017;23(1):52–59.
35.
Leslie-MazwiTMChandraRVOhDC, et al.Novel use of prasugrel for intracranial stent thrombosis. J Neurointerv Surg. 2011;3(4):358–360.
36.
ÇabalarMResulovaATaşdemirN, et al.Stenting for severe vertebral artery orifice stenosis in a case of three cerebral artery occlusion. Istanbul Med J. 2017;18(1):44–46.
37.
AtallahESaadHBekelisK, et al.The use of alternatives to clopidogrel in flow-diversion treatment with the pipeline embolization device. J Neurosurg. 2018;129(5):1130–1135.
38.
CannonCPHarringtonRAJamesS, et al.Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet. 2010;375(9711):283–293.
39.
HanelRATausskyPDixonT, et al.Safety and efficacy of ticagrelor for neuroendovascular procedures. A single center initial experience. J Neurointerv Surg. 2014;6:320–322.
40.
GhamasaeePCarrKJohnsonJ, et al.Malignant stroke in a ticagrelor non-responder as a complication following aneurysm treatment with the Pipeline Embolization Device™. Interv Neuroradiol. 2017;23(3):297–300.
41.
OlafsonEMDeGroteJRDrofaA, et al.A case series of 18 patients receiving ticagrelor after carotid stenting. J Pharm Pract. 2018;31:519–521.
42.
DavisKMorrisonC. Ticagrelor for neuroendovascular procedures: a case series. J Pharm Pract. 2018;31(1):115–119.
43.
NarataAPAmelotABibiR, et al.Dual antiplatelet therapy combining aspirin and ticagrelor for intracranial stenting procedures: a retrospective single center study of 154 consecutive patients with unruptured aneurysms. Neurosurgery. 2019;84(1):77–83.
